Market Risers: Centralnic Group, GlaxoSmithKline, GSTechnologies Ltd, Imperial Brands

Broker Ratings

The trading price for Centralnic Group ticker lookup code: LON:CNIC has risen 6.47% or 5.5 points throughout today’s trading session so far. Buyers seem confident during the session. The period high was 90.5 and a low of 85.55. The total volume of shares exchanged through this period comes to 61,974 while the daily average number of shares exchanged is 202,841. A 52 week high for the stock is 99.5 around 14.5 points different to the previous business close and a 52 week low sitting at 57 which is a variance of 28 points. Centralnic Group has a 20 day moving average of 88.27 and now the 50 day moving average at 85.53. The market capitalisation is now £211.53m at the time of this report. The currency for this stock is Great British pence.Market cap is measured in GBP. This article was written with the last trade for Centralnic Group being recorded at Monday, December 7, 2020 at 11:52:55 AM GMT with the stock price trading at 90.5 GBX.

The stock price for GlaxoSmithKline ticker code: LON:GSK has stepped up 2.07% or 28.75 points during today’s session so far. Market buyers have so far held a positive outlook during the session. Range high for the period has seen 1418.6 dropping as low as 1391.4. The volume total for shares traded up to this point was 2,087,896 with the daily average at 11,923,308. The 52 week high is 1857 which comes in at 471 points in difference on the previous days close and a 52 week low being 1284 making a difference of 102 points. GlaxoSmithKline now has a 20 moving average of 1421.11 and also a 50 day SMA of 1416.39. This puts the market cap at £70,984.10m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for GlaxoSmithKline being recorded at Monday, December 7, 2020 at 12:29:57 PM GMT with the stock price trading at 1414.75 GBX.

The trading price for GSTechnologies Ltd ticker code: LON:GST has stepped up 5.38% or 0.01 points throughout today’s trading session so far. Market buyers are a positive bunch throughout the session. The periods high figure was 0.14 meanwhile the session low reached 0.12. The total volume of shares traded by this point was 710,599 with the average number of shares traded daily being 2,481,904. The stock 52 week high is 0.27 which is 0.14 points difference from the previous days close and the 52 week low at 0.11 is a variance of 0.02 points. GSTechnologies Ltd now has a 20 simple moving average of 0.17 and also a 50 day moving average of 0.21. The current market capitalisation is £1.36m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for GSTechnologies Ltd being recorded at Monday, December 7, 2020 at 11:00:23 AM GMT with the stock price trading at 0.14 GBX.

The trading price for Imperial Brands found using EPIC: LON:IMB has risen 2.72% or 39.84 points throughout today’s trading session so far. Market buyers have remained positive during this period. The periods high has already touched 1512.12 dropping as low as 1460.5. The total volume of shares traded by this point was 845,610 while the daily average number of shares exchanged is 2,870,592. The 52 week high is 2072 which comes in at 605 points difference from the previous days close and the 52 week low at 1203 making a difference of 264 points. Imperial Brands now has a 20 moving average of 1439.49 and a 50 day moving average at 1371.58. The current market capitalisation is £14,260.83m at the time of this report. The currency for this stock is Great British pence.Market cap is measured in GBP. This article was written with the last trade for Imperial Brands being recorded at Monday, December 7, 2020 at 12:29:45 PM GMT with the stock price trading at 1506.84 GBX.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

GSK’s Shingrix Prefilled Syringe Approved in Europe

GSK has received European Commission approval for a prefilled syringe presentation of its Shingrix shingles vaccine.

GSK Plc receives China approval for Nucala in COPD treatment

GSK plc has announced that China’s National Medical Products Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with inadequately controlled COPD characterised by raised blood eosinophils.

GSK Plc reaches US agreement to reduce prescription medicine costs

GSK has entered into an agreement with the US Administration to lower the cost of prescription medicines for American patients, including treatments across its respiratory portfolio for asthma and COPD.

GSK secures FDA approval for Exdensur in severe eosinophilic asthma

GSK plc has received US FDA approval for Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in patients aged 12 and over.

GSK Plc secures UK approval for Exdensur in asthma and nasal polyps

GSK has announced that Exdensur (depemokimab) has received marketing authorisation from the UK MHRA for use in certain asthma and chronic rhinosinusitis with nasal polyps patients.

GSK RSV vaccine recommended for wider adult use, CHMP backs expansion

GSK has announced that the EMA’s CHMP has recommended broadening the indication of its adjuvanted RSV vaccine to adults aged 18 and over, with a final decision expected in February 2026.

Search

Search